Deutsche Bank raises target for Lonza Group stock to CHF 715.00

Published on 10/20/2026 at 09:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza targets 10-13 percent organic growth and a 33-34 percent margin for 2026. Lonza Group stock costs EUR 660.00 on October 20, 2026.

Analyst targets and growth plans

Deutsche Bank raised its Lonza target from CHF 697.00 to CHF 715.00 on October 17, 2026.
Lonza targets 10-13 percent organic growth and a 33-34 percent core EBITDA margin for fiscal year 2026.
Lonza Group stock was trading at EUR 660.00 at 9:06 a.m. CEST at Lang & Schwarz on October 20, 2026.
Lonza plans to publish fiscal year 2026 results on January 27, 2027.
Lonza had a market capitalization of CHF 42.8 billion as of October 19, 2026.

Modernes Biotech-Produktionsgebäude mit Glas-Beton-Fassade, minimalistisch und funktional — Lonza CH0013841017 modernes Biotech Werk mit Glas Beton Fassade sauber und funktional, Illustration mit AI erstellt.

Lonza Group (ISIN CH0013841017) is trading at EUR 660.00 at Lang & Schwarz on October 20, 2026 at 9:06 a.m. CEST, while Deutsche Bank raised its price target from CHF 697.00 to CHF 715.00. Börse Express reported the target increase on October 17, 2026.

Analysts lift their targets

The Deutsche Bank move followed Lonza's October 14 Capital Markets Day, when the company presented a higher medium-term ambition. The bank kept its Buy recommendation while lifting the target to CHF 715.00 from CHF 697.00. Rothschild & Co Redburn also raised its target from CHF 670.00 to CHF 690.00, according to Börse Express.

What changes for margins?

Lonza now targets average organic sales growth of 10-13 percent at constant exchange rates over the medium term and a core EBITDA margin in the high thirties. For fiscal year 2026, the company reaffirmed its outlook for 11-12 percent constant-currency sales growth and a 33-34 percent core EBITDA margin. The figures come from the company announcement dated October 14, 2026, published by FT.com.

Three milestones frame the story

On July 22, 2026, Lonza reported half-year sales of CHF 3.4 billion and core EBITDA of CHF 1.2 billion in its investor-relations archive. On October 12, 2026, the company expanded its dual-payload antibody-drug-conjugate technology offering. On October 14, 2026, Lonza confirmed that third-quarter performance was in line with expectations and reaffirmed its full-year outlook, as detailed by FT.com.

Next reporting date is January 27

Lonza has scheduled publication of its fiscal year 2026 results for January 27, 2027. That report will test whether the 11-12 percent growth outlook and 33-34 percent core EBITDA margin are translating into reported results. The next step is therefore operational delivery rather than another change to the medium-term model.

Stock trades at EUR 660.00

Lonza Group stock was trading at EUR 660.00 at Lang & Schwarz on October 20, 2026 at 9:06 a.m. CEST. The company's primary listing is on the SIX Swiss Exchange, where the finance quote showed a 52-week range of CHF 454.60 to CHF 613.20 and a market capitalization of CHF 42.8 billion as of October 19, 2026.

The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.